<DOC>
	<DOCNO>NCT01742598</DOCNO>
	<brief_summary>The purpose study assess safety performance 23mm Portico Transcatheter Heart Valve TAVI Transapical Delivery System subject severe symptomatic aortic stenosis</brief_summary>
	<brief_title>Assessment St Jude Medical Portico Re-sheathable Transapical Aortic Valve System</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject sign study Informed Consent Form Data Protection Form prior participate study . 2 . Subject 65 year age old time index procedure , and/or comorbidities , opinion Principal Investigator Subject Selection Committee , preclude surgical valve replacement . 3 . Subject 's aortic annulus 1921mm diameter measure echocardiography ( echo ) CT conduct within 90 day prior index procedure . 4 . Subject senile degenerative aortic stenosis echocardiography derive mean gradient great ( &gt; ) 40mmHg jet velocity great 4.0 m/s initial valve area le ( &lt; ) 0.8 cm2 ( aortic valve area index less equal ( ≤ ) 0.6 cm2/m2 ) . ( Baseline measurement take echo within 90 day index procedure ) . 5 . Subject symptomatic aortic stenosis demonstrate NYHA Functional Classification II , III , IV . 6 . Subject deem high operable risk suitable TAVI per medical opinion Subject Selection Committee . 7 . Subject 's predicted operative mortality serious , irreversible morbidity risk le ( &lt; ) 50 % 30 day post index procedure . 1 . Subject unwilling unable comply studyrequired followup evaluation . 2 . Subject documented history cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within 6 month ( less equal ( ≤ ) 180 day ) prior index procedure . 3 . Subject chest condition prevents transapical access . 4 . Subject carotid artery disease require intervention . 5 . Subject document evidence myocardial infarction ( MI ) within 6 month ( less equal ( ≤ ) 180 day ) prior index procedure . 6 . Subject native aortic valve congenitally unicuspid , bicuspid , quadricuspid noncalcified see echocardiography . 7 . Subject mitral valvular regurgitation great ( &gt; ) grade III . 8 . Subject moderate severe mitral stenosis . 9 . Subject aortic root angulation great ( &gt; ) 70 degree ( horizontal aorta ) . 10 . The distance leave ventricular apex aortic annulus le ( &lt; ) 45mm ( 4.5cm ) . 11 . Subject preexist prosthetic cardiac device , valve , prosthetic ring position . 12 . Subject refuse blood product transfusion . 13 . Subject refuse surgical valve replacement . 14 . Subject leave ventricular ejection fraction ( LVEF ) less ( &lt; ) 20 % . 15 . Subject document , untreated symptomatic coronary artery disease ( CAD ) require revascularization . 16 . Subject percutaneous interventional invasive cardiovascular peripheral vascular procedure less equal ( ≤ ) 14 day index procedure . 17 . Subject severe basal septal hypertrophy would interfere transcatheter valve placement . 18 . Subject history , currently diagnose endocarditis . 19 . Subject image evidence intracardiac mass , thrombus , vegetation . 20 . Subject consider hemodynamically unstable ( require inotropic support mechanical heart assistance ) . 21 . Subject acute pulmonary edema require intravenous diuretic therapy stabilize heart failure . 22 . Subject significant pulmonary disease determine documented Investigator . 23 . Subject significant chronic steroid use determine documented Investigator . 24 . Subject documented hypersensitivity contraindication anticoagulant antiplatelet medication . 25 . Subject renal insufficiency evidence serum creatinine great ( &gt; ) 3.0 mg/dL ( 265.5µmol/L ) endstage renal disease require chronic dialysis . 26 . Subject morbid obesity define BMI great equal ( ≥ ) 40 . 27 . Subject ongoing infection sepsis . 28 . Subject blood dyscrasia ( e.g. , leukopenia , acute anemia , thrombocytopenia , history bleeding diathesis , coagulopathy ) . 29 . Subject current autoimmune disease , opinion Principal Investigator Subject Selection Committee , precludes subject study participation . 30 . Significant ascend aortic disease document diameter great 40mm . 31 . Subject active peptic ulcer gastrointestinal ( GI ) bleed within 90 day prior index procedure . 32 . Subject currently participate another investigational drug device study . 33 . Subject require emergency surgery reason . 34 . Subject life expectancy le ( &lt; ) 12 month . 35 . Subject medical , social psychological condition , opinion Principal Investigator Subject Selection Committee , preclude subject study participation . 36 . Subject diagnose dementia admit chronic care facility would fundamentally complicate rehabilitation procedure compliance followup visit . 37 . Subject document allergy contrast medium , nitinol alloy , porcine tissue , bovine tissue .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>TAVI</keyword>
	<keyword>TAVR</keyword>
	<keyword>aortic stenosis</keyword>
	<keyword>Transcatheter</keyword>
	<keyword>valvular heart disease</keyword>
	<keyword>aortic valve stenosis</keyword>
	<keyword>aortic valve replacement</keyword>
	<keyword>transcatheter aortic valve implantation</keyword>
</DOC>